Also known as: NCCN
FDA approves AstraZeneca and Daiichi Sankyo's Datroway for first-line TNBC patients not eligible for PD-1/L1 inhibitors, based on Phase III TROPION-Breast02 data showing a 21% reduction in risk of death versus chemotherapy.
Research found variation in guideline-concordant colorectal cancer care across hospitals and systems, while a separate study highlighted the role of specialized cancer nurses in reducing distress and improving support.
Compass Therapeutics reported mixed Phase 2/3 data for tovecimig in biliary tract cancer and plans to meet with the FDA for a BLA discussion. The study met its primary ORR endpoint (17% vs 5%), while PFS and OS data are due late this quarter.
A study in stage 3 dMMR colon cancer found that atezolizumab plus chemotherapy after surgery cut recurrence and death risk by 50%. The trial enrolled 712 patients and the regimen is now included in treatment guidelines.
The National Comprehensive Cancer Network has updated its bladder cancer guidelines to include ImmunityBio's Anktiva plus BCG for BCG-unresponsive papillary-only disease. The Category 2A recommendation expands treatment options beyond the drug's initial FDA approval for carcinoma in situ. ImmunityBio also announced its pivotal trial is adequately powered and European distribution partnerships to expand global access.
New research demonstrates blood-based biomarkers can predict testicular cancer recurrence and treatment outcomes, while separate study reveals long-term health risks vary by chemotherapy regimen in survivors.
New research shows cancer survivors who exercise reduce their risk of cancer-related death, while expert panel recommends exercise as essential for older cancer patients during and after treatment.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07549139 |
Overcoming Racial Disparities in Screening Mammography |
NOT_YET_RECRUITING | NA |
| NCT07146646 |
Trifluridine/Tipiracil + Oxaliplatin in Participants With Advanced or Metastatic Biliary Tract Cancer |
RECRUITING | PHASE2 |
| NCT07030400 |
Predictors of Health-Related QOL in Adults With CLL or Small Lymphocytic Lymphoma |
RECRUITING | |
| NCT06682390 |
Role of Race in Nutritional Approach in Men on ADT |
RECRUITING | NA |
| NCT06650579 |
REVELUTION-2: Relugolix+Abiraterone Acetate (AA) Versus Leuprolide+AA Cardiac Trial |
RECRUITING | PHASE3 |
| NCT06483100 |
Measurable Residual Disease-Guided Post-Transplant Elranatamab Maintenance |
RECRUITING | PHASE2 |
| NCT06463457 |
Comeback From Long coursE Androgen Deprivation Therapy (ADT) With RElugolix and Darolutamide (CLEARED) |
ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT06396598 |
Electronic Symptom Monitoring Program for Triggered Palliative Referrals in Patients With Thoracic Cancer |
RECRUITING | NA |
| NCT06202820 |
CV CARE: CardioVascular Care in PC Patients |
RECRUITING | NA |
| NCT06138561 |
Management of Cisplatin-Ineligible Patients With Metastatic Bladder Cancer and The Role of Geriatric Assessments |
RECRUITING |
